Sulfonylurea Hypoglycemic Agent Antidiabetic API Gliclazide CAS 21187-98-4


Product Name:Gliclazide
Synonyms:)-4-methyl-;1-(3-azabicyclo(3.3.0)oct-3-yl)-3-(p-tolylsulfonyl)urea;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)-ure;1-(hexahydrocyclopenta(c)pyrrol-2(1h)-yl)-3-(p-tolylsulfonyl)urea;benzenesulfonamide,n-(((hexahydrocyclopenta(c)pyrrol-2(1h)-yl)amino)carbonyl;n-(4-methylbenzenesulfonyl)-n'-(3-azabicyclo(3.3.0)oct-3-yl)urea;s852;se1702
CAS:21187-98-4
MF:C15H21N3O3S
MW:323.41
EINECS:244-260-5
Product Categories:Pharmaceutical;Active Pharmaceutical Ingredients;APIs;
Intermediates & Fine Chemicals;Pharmaceuticals;API's;Potassium channel;Aromatics;Sulfur & Selenium Compounds;Other APIs;Pharmaceutical intermediates;Anti diabetic
Melting point: 163-169 C(lit.)
Chemical Properties: White Cyrstalline Solid
Uses: antidiabetic, adhesion inhibitor.
Uses: A sulfonylurea hypoglycemic agent. Used as an antidiabetic.


Gliclazide Description

Gliclazide is an oral antihyperglycemic agent used for the treatment of diabetes mellitus type II. It belongs to the sulfonylurea class of insulin secretagogues, which stimulates cells of the pancreas to release insulin. Gliclazide binds to the cell sulfonyl urea receptor (SUR1), further blocking the ATP sensitive potassium channels. Therefore, the potassium efflux substantially decreases, causing depolarization of the cells. Then the voltage-dependent calcium channels in the cell are open, resulting in calmodulin activation, which in turn leads to exocytosis of insulin containing secretorty granules. Recent studies have also shown that gliclazide can effectiveimprove anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes and protect pancreatic beta-cells from damage by hydrogen peroxide.


Hypoglycemic agents

Gliclazide, chemical name is 1-(hexahydrocyclopenta [c] pyrrole-2 (1H)-yl)-3-(4-methylphenyl) sulfonyl urea, is the second generation of sulfur ureide oral hypoglycemic agents, and it also has dual function of hypoglycemic and improving blood clotting. It not only can improve the metabolism of diabetic patients, but also can improve or delay the occurrence of diabetic vascular complications. Gliclazide was developed by the French SERVIER company, and listed in France as early as 1972. Its trade names are diamicron gliclazide, methanesulfonic bicyclic urea to g pancreas, methanesulfonic grid urea, glick that sa. It is mainly used for the treatment of the onset of diet and exercise alone control ineffective of adulthood, and no ketosis tendency of light, moderate the type II diabetes. It also can improve diabetic retinopathy and metabolic disorders, vascular function. It can be used with biguanide oral hypoglycemic drugs, and used with insulin to treat insulin-dependent diabetes mellitus, in which condition that insulin dosage can be reduced. 1980s, it began to be supplied into the Chinese market. Now there has been more than 130 countries worldwide that registered and sold.


Gliclazide Uses

1. for adults with type 2 diabetes, diabetes associated with obesity or vascular lesions.
2. Hypoglycemic agents. It can be used for the treatment of non-insulin dependent diabetes mellitus.
3. Hypoglycemic agents, non-insulin dependent diabetes mellitus.